O-mannosylation of the Mycobacterium tuberculosis Adhesin Apa Is Crucial for T Cell Antigenicity during Infection but Is Expendable for Protection

Nandakumar, Subhadra; Kannanganat, Sunil; Dobos, Karen M.; Lucas, Megan; Spencer, John S.; Fang, Sunan; McDonald, Melissa A.; Pohl, Jan; Birkness, Kristin; Chamcha, Venkateswarlu; Ramirez, Melissa V.; Plikaytis, Bonnie B.; Posey, James E.; Amara, Rama Rao; Sable, Suraj B.

doi:10.1371/journal.ppat.1003705

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

O-mannosylation of the Mycobacterium tuberculosis Adhesin Apa Is Crucial for T Cell Antigenicity during Infection but Is Expendable for Protection

Published Date:

Oct 10 2013

Publisher's site:

http://dx.doi.org/10.1371/journal.ppat.1003705 New Site Icon

Source:

PLoS Pathog. 2013; 9(10).

[PDF-1.93 MB]

Details:

Personal Authors:

Nandakumar, Subhadra ; Kannanganat, Sunil ; Dobos, Karen M. ; Lucas, Megan ; Spencer, John S. ; ... More ▼

Keywords:

[+]

Description:

Glycosylation is the most abundant post-translational polypeptide chain modification in nature. Although carbohydrate modification of protein antigens from many microbial pathogens constitutes important components of B cell epitopes, the role in T cell immunity is not completely understood. Here, using ELISPOT and polychromatic flow cytometry, we show that O-mannosylation of the adhesin, Apa, of Mycobacterium tuberculosis (Mtb) is crucial for its T cell antigenicity in humans and mice after infection. However, subunit vaccination with both mannosylated and non-mannosylated Apa induced a comparable magnitude and quality of T cell response and imparted similar levels of protection against Mtb challenge in mice. Both forms equally improved waning BCG vaccine-induced protection in elderly mice after subunit boosting. Thus, O-mannosylation of Apa is required for antigenicity but appears to be dispensable for its immunogenicity and protective efficacy in mice. These results have implications for the development of subunit vaccines using post-translationally modified proteins such as glycoproteins against infectious diseases like tuberculosis.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

HHSN266200400091C/PHS HHS/United States
R01 AI071852/AI/NIAID NIH HHS/United States
U19 AI074073/AI/NIAID NIH HHS/United States

Supporting Files:

	ppat.1003705.g004.jpg	image/jpeg
	ppat.1003705.g005.gif	image/gif
	ppat.1003705.g005.jpg	image/jpeg
	ppat.1003705.g006.gif	image/gif
	ppat.1003705.g006.jpg	image/jpeg
	ppat.1003705.g007.gif	image/gif
	ppat.1003705.g007.jpg	image/jpeg
	ppat.1003705.g008.gif	image/gif
	ppat.1003705.g008.jpg	image/jpeg
	ppat.1003705.nxml	text/plain
	license.txt	text/plain
	ppat.1003705.s001.tif	image/tiff
	ppat.1003705.s002.tif	image/tiff
	ppat.1003705.s003.tif	image/tiff
	ppat.1003705.s004.tif	image/tiff
	ppat.1003705.s005.tif	image/tiff
	ppat.1003705.s006.tif	image/tiff
	ppat.1003705.s007.docx	application/vnd.openxmlformats-officedocument.wordprocessingml.document
	ppat.1003705.g001.gif	image/gif
	ppat.1003705.g001.jpg	image/jpeg
	ppat.1003705.g002.gif	image/gif
	ppat.1003705.g002.jpg	image/jpeg
	ppat.1003705.g003.gif	image/gif
	ppat.1003705.g003.jpg	image/jpeg
	ppat.1003705.g004.gif	image/gif

No Related Documents.

You May Also Like:

Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis

Personal Author:

Nandakumar, Subhadra; Kannanganat, Sunil; Dobos, Karen M.; Lucas, Megan; Spencer, John S.; Amara, Rama Rao; Plikaytis, Bonnie B.; Posey, James E.; Sable, Suraj B.;

Published:

May 13 2016

Source:

Sci Rep. 2016; 6.

Description:

Heterologous prime-boosting has emerged as a powerful vaccination approach against tuberculosis. However, optimal timing to boost BCG-immunity using subunit vaccines remains unclear in clinical trials. Here, we followed the adhesin Apa-specific T-cel...

File Type:

[PDF - 2.17 MB]
Cellular Immune Responses to Nine Mycobacterium tuberculosis Vaccine Candidates following Intranasal Vaccination

Personal Author:

Sable, Suraj B.; Cheruvu, Mani; Nandakumar, Subhadra; Sharma, Sunita; Bandyopadhyay, Kakali; Kellar, Kathryn L.; Posey, James E.; Plikaytis, Bonnie B.; Amara, Rama Rao; Shinnick, Thomas M.;

Published:

Jul 25 2011

Source:

PLoS One. 2011; 6(7).

Description:

Background : The identification of Mycobacterium tuberculosis vaccines that elicit a protective immune response in the lungs is important for the development of an effective vaccine against tuberculosis. : Methods and Principal Findings : In this stu...

File Type:

[PDF - 857.64 KB]
Attrition of T-Cell Functions and Simultaneous Upregulation of Inhibitory Markers Correspond with the Waning of BCG-Induced Protection against Tuberculosis in Mice

Personal Author:

Nandakumar, Subhadra; Kannanganat, Sunil; Posey, James E.; Amara, Rama Rao; Sable, Suraj B.;

Published:

Nov 24 2014

Source:

PLoS One. 2014; 9(11).

Description:

Mycobacterium bovis bacille Calmette-Guérin (BCG) is the most widely used live attenuated vaccine. However, the correlates of protection and waning of its immunity against tuberculosis is poorly understood. In this study, we correlated the longitudi...

File Type:

[PDF - 4.00 MB]
TB notes ; 2013, no. 4

Corporate Author:

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.

Published:

12/20/2013

Series:

TB notes ; 2013, no. 4

Description:

Highlights from state and local programs -- Bedaquiline, a new drug for MDR TB -- NTCA responds to the shortages of TB drugs and diagnostics -- TB Education and Training Network updates -- TB Epidemiologic Studies Consortium updates -- Communications...

File Type:

[PDF - 1.74 MB]
Emerging Vaccine Informatics

Personal Author:

He, Yongqun; Rappuoli, Rino; De Groot, Anne S.; Chen, Robert T.;

Published:

Jun 15 2011

Source:

J Biomed Biotechnol. 2010; 2010.

Description:

Vaccine informatics is an emerging research area that focuses on development and applications of bioinformatics methods that can be used to facilitate every aspect of the preclinical, clinical, and postlicensure vaccine enterprises. Many immunoinform...

File Type:

[PDF - 930.92 KB]